A M R Schrader1, P M Jansen1, R Willemze2. 1. Department of Pathology, Leiden University Medical Centre, Leiden, the Netherlands. 2. Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands.
Abstract
BACKGROUND: TOX (thymocyte selection-associated high-mobility group box) was shown to be aberrantly expressed in mycosis fungoides (MF) and Sézary syndrome (SS) and is suggested to have additional diagnostic value. However, data on expression in other types of cutaneous T-cell lymphoma (CTCL) are scarce and it is unknown whether TOX is expressed only by MF with a CD4(+) CD8(-) phenotype. OBJECTIVES: To investigate TOX expression in various types of CTCL with different T-cell phenotypes. METHODS: Immunohistochemical expression of TOX was evaluated on 153 skin biopsies of 132 patients with CTCL and 60 patients with benign inflammatory dermatoses (BIDs). RESULTS: TOX was expressed by > 50% of the neoplastic T cells in 49 of 59 patients (83%) with MF and in 19 of 22 patients (86%) with SS. The TOX(+) cases of MF included 34 of 35 cases (97%) with a CD4(+) CD8(-) phenotype, but also five of eight cases (63%) with a CD4(-) CD8(+) phenotype and 10 of 16 cases (63%) with a CD4(-) CD8(-) phenotype. TOX expression in other types of CTCL was common but showed variable intensity. Although only one of 60 patients (2%) with a BID expressed TOX in > 50% of the skin-infiltrating T cells, some caution is warranted, as the majority of BIDs had TOX(+) T cells varying between 11% and 50%. CONCLUSIONS: TOX expression is not tumour specific, is not restricted to CTCL with a CD4(+) CD8(-) phenotype, and, on its own, is insufficient for diagnosis of CTCL. However, it may have an adjunctive diagnostic role in conjunction with other clinical and histological data.
BACKGROUND:TOX (thymocyte selection-associated high-mobility group box) was shown to be aberrantly expressed in mycosis fungoides (MF) and Sézary syndrome (SS) and is suggested to have additional diagnostic value. However, data on expression in other types of cutaneous T-cell lymphoma (CTCL) are scarce and it is unknown whether TOX is expressed only by MF with a CD4(+) CD8(-) phenotype. OBJECTIVES: To investigate TOX expression in various types of CTCL with different T-cell phenotypes. METHODS: Immunohistochemical expression of TOX was evaluated on 153 skin biopsies of 132 patients with CTCL and 60 patients with benign inflammatory dermatoses (BIDs). RESULTS:TOX was expressed by > 50% of the neoplastic T cells in 49 of 59 patients (83%) with MF and in 19 of 22 patients (86%) with SS. The TOX(+) cases of MF included 34 of 35 cases (97%) with a CD4(+) CD8(-) phenotype, but also five of eight cases (63%) with a CD4(-) CD8(+) phenotype and 10 of 16 cases (63%) with a CD4(-) CD8(-) phenotype. TOX expression in other types of CTCL was common but showed variable intensity. Although only one of 60 patients (2%) with a BID expressed TOX in > 50% of the skin-infiltrating T cells, some caution is warranted, as the majority of BIDs had TOX(+) T cells varying between 11% and 50%. CONCLUSIONS:TOX expression is not tumour specific, is not restricted to CTCL with a CD4(+) CD8(-) phenotype, and, on its own, is insufficient for diagnosis of CTCL. However, it may have an adjunctive diagnostic role in conjunction with other clinical and histological data.
Authors: Ivan V Litvinov; Michael T Tetzlaff; Philippe Thibault; Pamela Gangar; Linda Moreau; Andrew K Watters; Elena Netchiporouk; Kevin Pehr; Victor G Prieto; Elham Rahme; Nathalie Provost; Martin Gilbert; Denis Sasseville; Madeleine Duvic Journal: Oncoimmunology Date: 2017-03-17 Impact factor: 8.110
Authors: Andrea M Moerman-Herzog; Daniel A Acheampong; Amanda G Brooks; Suzan M Blair; Ping-Ching Hsu; Henry K Wong Journal: Oncotarget Date: 2019-08-20
Authors: Enrique Huanosta-Murillo; Marcela Alcántara-Hernández; Brenda Hernández-Rico; Georgina Victoria-Acosta; Patricia Miranda-Cruz; María Antonieta Domínguez-Gómez; Fermín Jurado-Santacruz; Genaro Patiño-López; Vadim Pérez-Koldenkova; Alam Palma-Guzmán; Paula Licona-Limón; Ezequiel M Fuentes-Pananá; Alicia Lemini-López; Laura C Bonifaz Journal: Front Immunol Date: 2021-06-16 Impact factor: 7.561